Inverse planning optimization using biologically based objectives is becoming part of the intensity modulated optimization process. The performances and efficacy of the biologically based gEUD (generalized Equivalent Uniform Dose) objective implemented in the Photon Optimizer (PO) of Varian Eclipse treatment planning system have been here analyzed. gEUD is associated with the parameter a that accounts for the seriality of a structure, being higher for more serial organs. The PO was used to optimize volumetric modulated arc therapy (VMAT) plans on a virtual homogeneous cylindrical phantom presenting a target and an organ at risk (OAR). The OAR was placed at 4 mm, 1 and 2 cm distance, or cropped at 0, 2 and 4 mm from the target. Homogeneous target dose of 60 Gy in 20 fractions was requested with physical dose-volume objectives, while OAR dose was minimized with the upper gEUD objective. The gEUD specific a parameter was varied from 0.1 to 40 to assess its impact to OAR sparing and target coverage. Actual head and neck and prostate cases, with one parotid and the rectum as test OAR, were also analyzed to translate the results in the more complex clinical environment. Increasing the a parameter value in the gEUD objective, the optimization achieved lower volumes of the OAR which received the highest dose levels. The maximum dose in the OAR was minimized well with a values up to 20, while further increase of a to 40 did not further improve the result. The OAR mean dose was reduced for the OAR located at 1 and 2 cm distance from the target, enforced with increasing a. For cropped OARs, a mean dose reduction was achieved for a values up to 3-5, but mean dose increased for higher a values. The optimal choice of the parameter a depends on the mutual OAR and target position, and seriality of the organ. Today no significant compendium of clinical and biological specific a and gEUD values are available for a wide range of OARs. 
Intensity modulation radiotherapy planning, in both fixed beam setting (IMRT) and volumetric modulated arc setting (VMAT), uses inverse optimization processes generally based on physical dose or dose-volume (DV) parameters. However, the planning criteria based on physical dose (or DV) constraints are a crude surrogate of any biological index that would better reflect the clinical goals. This makes the physical DV surrogates possibly inadequate to describe the radiation response of the tissues, and suboptimal to obtain a dose distribution that would aim to reflect more biological objectives. 1, 2 Dose-response models could be mechanistic, attempting to mathematically describe biological processes of cell survival, or phenomenological, empirically fitting available data. In the first group there are the normal tissue complication probability (NTCP) based model. The Lyman-Kutcher-Burman model 3 described the doseresponse curve with three parameters, based on uniform irradiation; in this case, dose volume histogram (DVH) reduction algorithms were necessary to account for the non-uniform dose distribution (an overview of those reduction models is, e.g., in 4 ). Differently, the Relative Seriality model 5 described the radiation response according to the damage and recovery of organ functional subunits. But the models which are the most used in the currently available biologically-based treatment planning belong to the phenomenological approach. In particular, the Equivalent Uniform Dose (EUD) concept proposed by Niemierko, 6 and its extension to gEUD (generalized EUD), 7 provides a single metric for reporting non-uniform dose distribution, using gEUD as a single organ specific parameter to account for the biological response according to the delivered dose distribution in that organ.
The inclusion of biologically-based constraints in the optimizer cost function driving the inverse planning process, inherently incorporating a specific volume effect, could allow shaping the dose distribution by balancing the amount of volume receiving different dose levels. However, the result of an inverse planning optimization depends on the complex interplay of all the terms of the cost function. It is essential in the clinical practice to understand the effects of the biologically based objectives in controlling the dose distribution, and to know which is the desirable final dose distribution for a proper use of the underlying model. Aim of the present work is to investigate the results, from a clinical perspective, of the performance and efficacy of the biologically based gEUD objective in Eclipse TM in the inverse planning process, as it is implemented in the current optimization engine. Experiments were conducted for a simplified phantom with the aim to achieve some specific dose sparing inside given organs. The same was applied to clinical cases of head and neck (with a parotid as organ at risk, OAR) and prostate (with the rectum as OAR) to check and compare the consistency with real clinical application.
| MATERIALS AND METHODS

2.A | The gEUD, generalized Equivalent Uniform Dose
The gEUD is defined as:
where v i is the fractional organ volume receiving a dose D i and a is a parameter that describes the volume effect. For a ! À1 (negative a values, down to À40 is available in practice), gEUD approaches the minimum dose, and can be used for tumors. For a ¼ 1, gEUD equals the mean dose, and could be used in place of the mean objective for parallel organs. For a ! þ1 (high a values, up to 40 in practice), gEUD tends to the maximum dose, and could be used to drive high (maximum) dose of serial organs.
The parameter a is organ specific, yet there are few specific studies to estimate the parameter values for the most important | 107 critical structures. However, it is related to the parameter n describing the volume effect in the Lyman-Kutcher-Burman NTCP model, as n ¼ 1=a. This last parameter has been widely analyzed, and a summary overview can be found in Luxton et al. 8 The concept of the gEUD optimization during inverse planning optimization is depicted in Fig. 1 : for the DVH on the left, the a parameter is equal to 1 and the optimization force is directed to reduce the volume receiving mid-dose levels, while, on the right DVH of the figure, the gEUD optimization with a high a parameter is shown to force the decrease in the structure volume receiving the higher dose levels. Regarding the specific implementation of the minimization of a convex optimization function (or non-convex of a global objective function), it is part of the non-disclosed implementation of the whole optimization engine.
2.B | The optimization objectives in PO
A number of different optimization objectives are available in PO (here used in its version 13.6). There are the physical constraints as
Upper, Lower, and Mean objectives used, respectively, to: limit the dose level in a defined portion of the structure volume, define a minimum dose level that a certain target volume should receive, define the mean dose that should not be exceeded for the structure.
The biological objectives are: Upper gEUD, Lower gEUD, and
Target gEUD. The parameter a can vary from +0.1 to +40 for Upper gEUD, from À40 to +1, excluding 0, for Lower gEUD and Target gEUD.
The exploration of the lower and target gEUD objectives is out of the scope of the present work, which aims to evaluate the capability of this tool to modulate, with one single objective, the shape of an OAR DVH. The target dose homogeneity was optimized in the current work with the only use of a lower and an upper physical DV constraint.
In the cost function, the different objectives are similarly handled in the Eclipse TM optimization engine as follows:
where W is a normalized non-linear function of priority, the actual values refer to the parameter during the optimization, the expected values refer to the settled objective. The total cost function is the summation of all the cost terms selected for optimization. 
2.C | The phantom study design
A virtual phantom with homogeneous Hounsfield Unit (HU) assignment equal to 0 was generated in Eclipse. It had cylindrical shape of 30 cm diameter and 50 cm long. In the middle of the phantom, a cylindrical target was delineated, of 10 cm diameter and length.
As organs at risk (OAR), different cylinders ( 4. Normal Tissue Objective: automatic, priority 100. This tool evaluates mean dose at concentric distances from targets and applies a penalty to voxels which exceed the mean dose of all voxels at the same distance. This generates a dose fall-off outside the target with a rather constant gradient from the target surface.
An additional plan was generated with a Mean objective to the OAR (dose 15 Gy, priority 70), to compare with the plan with upper gEUD with a = 1. Although the gEUD(1) equals the mean dose, the possible differences between the two applications are here explored.
No interactions were allowed during the optimization, which was left running for all the four multiple resolution levels without modifications nor level hold. The optimization resolution was set to 2.5 mm (normal setting). Final dose calculations used Acuros dose calculation algorithm (version 13.6) with 2.5 mm grid size. The ascription of 0 HU, with no specific material assignment, corresponds to the human tissue composed by 3% of adipose and 97% of muscle skeletal tissue. 9 Results on OAR dose distribution were reported as mean dose, gEUD (according to the varying a parameter), maximum point and near-to-maximum doses (as D 1% , D 2% , i.e., the dose received by 2% and the same cropped 4 mm by the target. New plans were generated optimizing the test OAR with the mean objective, or the upper gEUD objective, varying the a parameter value (1, 2, 3, 5, and 10). The priority was not made changing, as well as all the other optimization objectives. During the optimization no interactions were allowed, while it was possible to hold each of the resolution levels to permit the optimizer to achieve a flat cost, as during the routine clinical procedure.
The same parameters analyzed in the phantom study were here evaluated, and compared with those.
| RESULTS
3.A | Phantom study
In Fig. 3 i.e., the structures for which the optimization was driven.
The requested value of 15 Gy for the gEUD was achieved for any value of the parameter a only when the OAR was located far from the target (2 cm distance in the exercise), where a homogeneous dose was requested with higher priority. In the cases where the OAR was located closer to the target, the requested gEUD value was achieved only for very small a value, while increasing with a.
The mean dose (and similarly D 50% ) to the same OAR structure decreased for all OAR-target distances, until an a value of 3-5; then, for a 10 and higher, the mean structure dose increases with a for OAR distances cropped 0 to 4 mm from the target, while for OAR positioned from 4 mm to 2 cm from the target, the mean dose continuously decreases. On the other hand, the behavior of the maximum and near-to-maximum doses is different and continuously decreases with a. However, the maximum dose reaches an approximate plateau (around an a value of 10-20), beyond which the optimizer is not able to significantly reduce the dose further.
The trade-off due to the increased OAR sparing for high doses achieved by increasing the a value, especially when the OAR structure is close to the target, could be twofold. On one side, there is a diminished target homogeneity and coverage, as highlighted in Table 1 to the a = 20 case. Conversely, for a distant structure, for the same dose level requested, all the DVH smoothly decrease for a from 0.1 to its maximum value 40.
In the geometries studied, where an OAR is cropped to relatively distant, there is not much to gain from using an a parameter higher than 10 or 20. When using an a of 40, the maximal or near maximum dose of the OAR is nearly the same as that for a = 10 or a = 20, yet the mean dose is higher and target coverage is worse.
Comparing the plans optimized using the upper gEUD objective with a = 1 vs. the mean dose objective, differences were clearly present, showing that the different objectives (gEUD vs. mean dose) led to different terms in the cost function. Results are summarized in Table 2 . The variations were not negligible for the OAR maximum dose (or even near-to-maximum doses), where the mean objective resulted in higher maximum doses for OAR positioned 1 or 2 cm from the target, although the mean OAR dose was within 1.5% in all analyzed cases. Also the target dose homogeneity (evaluated as the standard deviation parameter), was shown to be better for upper gEUD objective plans in the cases where the OAR was cropped from the target.
3.B | Clinical cases
The 
| DISCUSSION
The use of the biological optimization parameter called "upper gEUD" was evaluated for OAR structures at different distances from the target during VMAT optimization in the Eclipse TM PO optimizer.
It shows to be a powerful objective tool to improve the OAR sparing without compromising the target coverage and homogeneity when applied with an a value selected according to the structure seriality and target/OAR geometry.
Biological DV objectives have been explored for other planning systems or ad-hoc optimization engines, presenting similar results.
The first applications of the gEUD concept 10, 11 showed that the EUD-based optimization was capable of improving the sparing of the critical structure, keeping the same target coverage, although for target dose homogeneity care should be paid for possible hot spots that has to be managed with additional constraints, balancing the trade-offs between target homogeneity and OAR sparing. clinical application of the use of gEUD-based optimization have been published. Widesott et al. 12 optimized prostate and head and neck IMRT plans, obtaining promising results using the parameter a = 1 in all cases, while not varying the a value to shape the optimized DVH.
Mihailidis et al. 13 optimized IMRT plans using gEUD-based objectives for OARs comparing the results to plans optimized using physical DV constraints for breast and chest wall planning treatments.
The authors concluded that gEUD-based plans allow greater sparing of the OARs while maintaining equivalent target coverage, with a reduction, e.g., from 22% to 18% of the V 20 Gy parameter for the ipsilateral lung. In 2012, Dogan 14 compared head and neck VMAT plans using Pinnacle with physical DV constraints and gEUD-based plans. The latter approach yielded 55% reduction in near-to-maximum cord dose, and 35% reduction in mean parotid dose. By varying the a value, they reported an increase of MU for gEUD-based plans by 12%, 19%, 21% for a set to 1, 5, and 10, respectively. In our current study, no net trend with a was shown for MU. Although a general modest increase with a seems to be present, this was not systematic. Again on Pinnacle, Lee 15 evaluated on 10 IMRT patients the differences between physical and gEUD-based optimization for bilateral breast planning, reporting a better OAR sparing with biological features, using fixed a values of 1 and 3 for lung and heart, respectively (Pinnacle default values for those structures). On
Eclipse, but using the specific biological optimization module based in TCP and NTCP (both Lyman and serial models), Kan 16 reported that for nasopharyngeal cancer IMRT planning, the biological optimization yielded comparable TCP, relative to physical optimization, while presenting more hot spots in the target, better NTCP for parotids, no significant difference for serial organs. Similar conclusions were outlined by Feng 17 for cervical cancer planning using IMRT and the same biological optimization module in Eclipse.
The biological optimization using gEUD, for both target and OAR, has been used by Cabrera G. et al. 18 
| 113
Some published values of the n parameter of the Lyman-KutcherBurman NTCP model could be considered as a starting value for the gEUD optimization as a "true" biological solution. However, there is a lack of knowledge in which is the gEUD(a) tolerance value for each specific organ. Since the gEUD(a) value depends on the DVH shape, there is no correlation between e.g., the mean dose and the gEUD.
This makes more difficult a correct use of the gEUD objective, once applied the proper organ-specific a value, as there is no published data on gEUD(a) tolerance levels for specific organs.
In this view, in light of more specifically biological evaluations, the gEUD objective in Eclipse TM can be safely used since it reduces the OAR dose to all involved dose levels for a values from 1 to~5. For lar-
ger a values, attention should be paid case by case, since, depending on the structures geometry and mutual locations, the DVH could be lower for some dose range and higher for other ranges.
For a more biologically conscious use of the gEUD-based optimization, and to give meaning to the gEUD dose in relation to a specific a parameter for each specific organ, we need clinical studies evaluating the patient toxicity related to gEUD and the a parameter for the most important critical structures. This will allow reducing better the doses to OAR, in the low or high dose range, where clinically and biologically it is more relevant in the specific structure, thanks to an improved knowledge of the biological and clinical effect of the radiation. For the moment, for the specific use of a, we could start from the fact that a = 1/n, and n values have been widely published and summarized. 8 The simplicity of the proposed phantom exercise allowed the understanding of the performance of the sole gEUD upper objective, without mixing or confounding different effects deriving from other sources anatomy related. However, the use of this tool to specific clinical cases was confirming the trends read in the phantom setting, now able to possibly distinguish between the tool performance and the anatomical specific features.
| CONCLUSIONS
The gEUD optimization objective implemented in the Eclipse PO optimizer has shown to be a powerful instrument to spare the OARs without reducing the target coverage. A better understanding of the correlation between the a parameter and the OAR radiobiology remains advisable.
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